• K V Kasyanenko, K V Kozlov, O V Maltsev, I I Lapikov, V V Gordienko, V V Sharabhanov, P V Sorokin, and K V Zhdanov.
• Kirov Military Medical Academy.
• Terapevt Arkh. 2021 Mar 15; 93 (3): 290294290-294.

AimIn this study we evaluated the effects of Riamilovir on SARS-CoV-2 viral shedding and on admission duration in patients with moderate COVID-19.Materials And MethodsWe have used data from 69 health records of patients with moderate severe PCR confirmed SARS-CoV-2 infection. Control group included 34 patients treated with off-label riamilovir 1250 mg per day for 5 days (250 mg 5 times a day), comparison groups 35 patients, who received ribavirin and umifenovir 800 mg a day for 5 days. The antiviral therapy was administered within 72 hours from the onset of the disease. The primary endpoints were elimination of virus in oropharyngeal and nasopharyngeal swabs on 7 day of admission and discharge from the hospital by 14 day.ResultsPatients assigned to riamilovir had significantly shorter time to clinical improvement as well as increased PCR negative rate by day 7.ConclusionYearly administration of riamilovir as opposed to the umifenovir and ribavirin in therapy of moderate SARS-CoV-2 infection was associated with significant shorter time to clinical improvement by 14 day of hospitalization. PCR negative rate by 7 days of hospitalization is significantly more likely in riamilovir group.

6 keywords...

hide…